Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE

SG&A Trends: Arrowhead vs. Evotec

__timestampArrowhead Pharmaceuticals, Inc.Evotec SE
Wednesday, January 1, 20142441953617990000
Thursday, January 1, 20153471808925166000
Friday, January 1, 20164099820927013000
Sunday, January 1, 20173202288042383000
Monday, January 1, 20181911005157012000
Tuesday, January 1, 20192655625766546000
Wednesday, January 1, 20205227589077238000
Friday, January 1, 202180981000105445000
Saturday, January 1, 2022124431000156190000
Sunday, January 1, 202390932000169610000
Monday, January 1, 202498761000
Loading chart...

Unleashing the power of data

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining competitive advantage. Arrowhead Pharmaceuticals, Inc. and Evotec SE, two prominent players, showcase distinct trajectories in their SG&A spending from 2014 to 2023.

Arrowhead Pharmaceuticals saw a remarkable increase in SG&A expenses, peaking in 2022 with a 410% rise from 2014. This surge reflects strategic investments in marketing and administrative capabilities. However, 2023 marked a slight dip, indicating potential cost optimization efforts.

Conversely, Evotec SE experienced a steady climb, with a 843% increase by 2023, underscoring its commitment to expanding operational infrastructure. Notably, 2024 data for Evotec SE is missing, hinting at ongoing financial recalibrations.

These insights reveal how strategic SG&A management can drive growth and sustainability in the competitive pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025